MoonLake Immunotherapeutics
NASDAQ:MLTX
43.97 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.013 | 0.012 | 0.005 | 0 |
| Gross Profit
| -0.013 | -0.012 | -0.005 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 31.789 | 42.049 | 35.524 | 0 |
| General & Administrative Expenses
| 22.321 | 23.012 | 21.657 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 18.026 | 0 |
| SG&A
| 22.321 | 23.012 | 18.048 | 0.106 |
| Other Expenses
| 0 | 0.592 | 0 | 0 |
| Operating Expenses
| 54.123 | 65.061 | 53.572 | 0.106 |
| Operating Income
| -54.123 | -65.061 | -53.577 | -0.106 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 10.138 | 0.592 | 10.654 | 0.015 |
| Income Before Tax
| -43.985 | -64.47 | -53.639 | -0.091 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.094 | 0.036 | 0.005 | -0.206 |
| Net Income
| -36.007 | -64.506 | -53.644 | -0.091 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -0.73 | -2.2 | -6.84 | -0.006 |
| EPS Diluted
| -0.73 | -2.2 | -6.84 | -0.006 |
| EBITDA
| -54.11 | -65.049 | -53.634 | -0.091 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |